Iodbenzal-dichlorid | 89692-78-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Iodbenzal-dichlorid
• 英文别名: [Dichloro(iodo)methyl]benzene
• CAS: 89692-78-4
• 化学式: C₇H₅Cl₂I
• 分子量: 286.927
• InChiKey: PHQDAZWFDUURQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  双(环戊二烯)钴 、 Iodbenzal-dichlorid 以 not given 为溶剂， 生成
  参考文献：
  名称：

  一氧化碳还原反应一氧化碳与有机卤化物

  摘要：

  钴茂与苄基，烯丙基和炔丙基卤化物（溴化物，碘化物，以及某些氯化物）反应非常顺利，从而形成环戊二烯基（1-外-有机基-环戊二烯）钴配合物。因此，利用苄基氯，苄基溴，反式-3-溴-1-苯基丙烯和3-溴-1-苯基丙炔，新的1-外-苄基，1-外-（反--3-苯基烯丙基）和1-获得环戊二烯基（环戊二烯）钴的外-（3-苯基炔丙基）衍生物。对于该反应，讨论了两步自由基机理。新化合物的组成源自其红外光谱和质谱图。

  DOI：

  10.1016/s0022-328x(00)81118-3

文献信息

• Trisubstituted pyrimidines
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US20030134838A1

  公开（公告）日：2003-07-17

  The present invention relates to trisubstituted pyrimidines of formula 1 wherein R a to R e are defined as in claim 1, which are suitable for the treatment of illnesses in which &bgr;-amyloid modulators have a therapeutic benefit, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

  本发明涉及式1的三取代嘧啶，其中R至Re的定义如权利要求1中所述，适用于治疗β-淀粉样蛋白调节剂具有治疗效益的疾病，用于制备具有上述特性的药物组合物的用途，以及其制备方法。
• Platinum(<scp>iv</scp>) N-heterocyclic carbene complexes: their synthesis, characterisation and cytotoxic activity
  作者：M. Bouché、G. Dahm、M. Wantz、S. Fournel、T. Achard、S. Bellemin-Laponnaz

  DOI：10.1039/c6dt01846g

  日期：——

  Platinum(II) N-heterocyclic carbene complexes have been oxidized by bromine or iodobenzene dichloride to provide the fully characterised corresponding platinum(IV) NHC complexes. Antiproliferative activities of Pt(IV) NHC complexes were assayed against several cancer cell lines and the results were correlated with respect to their stability. Mechanistic investigations revealed that mitochondrial dysfunction

  铂（II）N-杂环卡宾配合物已被溴或二氯化碘苯氧化，以提供特征充分的相应铂（IV）NHC配合物。Pt（IV）NHC复合物的抗增殖活性针对几种癌细胞进行了测定，结果与其稳定性相关。机理研究表明，线粒体功能障碍和ROS的产生与这些化合物诱导的细胞毒性过程有关。
• Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US20030045712A1

  公开（公告）日：2003-03-06

  The present invention relates to new substituted aryl and heteroaryl derivatives of general formula 1 wherein A, Ar, n, X, Y 1 , Y 2 , Y 3 , Y 4 , R 1 and R 5 are defined as in claim 1 , the prodrugs, the tautomers, stereoisomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable properties. Thus, the compounds of the above general formula I wherein R 5 does not contain a cyano group have, in particular, an antithrombotic effect and a selective factor Xa-inhibiting effect with generally improved compatibility. The compounds of the above general formula I wherein R 5 contains a cyano group are valuable intermediate products for preparing the antithrombotic compounds of general formula I.

  本发明涉及一种新的取代芳基和杂环芳基衍生物，其一般化学式为1，其中A、Ar、n、X、Y1、Y2、Y3、Y4、R1和R5如权利要求书中定义，其前药、互变异构体、立体异构体、它们的混合物及其盐，特别是其与具有有价值性能的无机或有机酸或碱的生理可接受的盐。因此，上述一般式I中的化合物，其中R5不含氰基，具有特别的抗血栓作用和选择性因子Xa抑制作用，并且通常具有改进的相容性。上述一般式I中的化合物，其中R5含有氰基，是制备一般式I抗血栓化合物的有价值的中间体。
• Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US20030004181A1

  公开（公告）日：2003-01-02

  Disubstituted bicyclic heterocycles of general formula I Ra—A-Het-B—Ar—E (I). Compounds of general formula I, wherein E is an R b NH—C(=NH)— group, have valuable pharmacological properties, particularly a thrombin-inhibiting effect and the effect of prolonging thrombin time, and those wherein E is a cyano group, are valuable intermediates for preparing the other compounds of general formula I.

  通式为IRa—A-Het-B—Ar—E（I）的双取代的杂环化合物。通式为I的化合物中，E为RbNH—C(=NH)—基团具有有价值的药理学特性，特别是抑制凝血酶的作用和延长凝血酶时间的作用，而E为氰基的化合物则是制备通式为I的其他化合物的有价值的中间体。
• New substituted indolinones, their manufacture and their use as medicaments
  申请人：Roth Juergen Gerald

  公开号：US20050009898A1

  公开（公告）日：2005-01-13

  The present invention relates to substituted indolinones of general formula wherein R 1 to R 6 and X are defined as in claim 1 , the isomers and the salts thereof, in particular the physiologically acceptable salts thereof which have valuable pharmacological properties, especially an inhibitory effect on various receptor-tyrosine kinases, and cycline/CDK complexes as well as on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一般式为R1至R6和X如权利要求1所定义的取代吲哚酮，其异构体和盐，特别是具有有价值的药理学性质，特别是对各种受体酪氨酸激酶和环蛋白/ CDK复合物以及内皮细胞和各种肿瘤细胞的增殖具有抑制作用的生理上可接受的盐，包含这些化合物的制药组合物，它们的用途和制备它们的过程。